.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
UBS
Harvard Business School
US Department of Justice
Colorcon
Cantor Fitzgerald
Queensland Health
Cerilliant
QuintilesIMS
Mallinckrodt

Generated: December 12, 2017

DrugPatentWatch Database Preview

LIPITOR Drug Profile

« Back to Dashboard

Which patents cover Lipitor, and what generic alternatives are available?

Lipitor is a drug marketed by Pfizer and is included in one NDA. There is one patent protecting this drug.

This drug has sixty-nine patent family members in thirty-six countries and ten supplementary protection certificates in seven countries.

The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty-one drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-001Dec 17, 1996ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-002Dec 17, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-001Dec 17, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-002Dec 17, 1996ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-004Apr 7, 2000ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-003Dec 17, 1996ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LIPITOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-002Dec 17, 1996► Subscribe► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-002Dec 17, 1996► Subscribe► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-001Dec 17, 1996► Subscribe► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-002Dec 17, 1996► Subscribe► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-003Dec 17, 1996► Subscribe► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-004Apr 7, 2000► Subscribe► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-002Dec 17, 1996► Subscribe► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-003Dec 17, 1996► Subscribe► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-004Apr 7, 2000► Subscribe► Subscribe
PfizerLIPITORatorvastatin calciumTABLET;ORAL020702-003Dec 17, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LIPITOR

Country Document Number Estimated Expiration
Israel177376► Subscribe
Colombia4700443► Subscribe
European Patent Office1148049► Subscribe
Slovakia284202► Subscribe
Japan3296564► Subscribe
Bulgaria63630► Subscribe
Hungary223599► Subscribe
World Intellectual Property Organization (WIPO)9703959► Subscribe
Argentina003458► Subscribe
Hong Kong1018052► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LIPITOR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0048France► SubscribePRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
C0118France► SubscribePRODUCT NAME: ATORVASTATINE CALCIQUE TRIHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 21960 DU 19970321; REGISTRATION NO/DATE AT EEC: PL 00018/0240 DU 19961107
545Luxembourg► SubscribePRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
C0103Belgium► SubscribePRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107
70034Netherlands► SubscribePRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
/1997Austria► SubscribePRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
/2006Austria► SubscribePRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN; NAT. REGISTRATION NO/DATE: 1-26271, 1-26273 20060330; FIRST REGISTRATION: FR 369300.9;369301.5; 369302.1;369303.8;369304.4;369305.0; 20050707
1003503/01Switzerland► SubscribePRODUCT NAME: AMLODIPIN + ATORVASTATIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57633 05.07.2006
30/2006Austria► SubscribePRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN
2014 00050Denmark► SubscribePRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
AstraZeneca
Novartis
Covington
Colorcon
Express Scripts
US Department of Justice
Cerilliant
Merck
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot